[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 268
Citations 0
Capitol Health Call
August 9, 2016

Legislation to Increase Generic Drug Alternatives

JAMA. 2016;316(6):575. doi:10.1001/jama.2016.10615

Legislation to deter brand-name pharmaceutical companies from blocking more affordable generic alternatives has been introduced in the Senate.

Sen Patrick Leahy (D, Vt) introduced the legislation under the act titled CREATES—Creating and Restoring Equal Access to Equivalent Samples—with Sen Chuck Grassley (R, Iowa), Sen Amy Klobuchar (D, Minn), and Sen Mike Lee (R, Utah).

“Our CREATES Act targets predatory delay tactics that some brand-name drug manufacturers are using to block competition from more affordable generic drugs,” Leahy, ranking member of the Senate Judiciary Committee, said in a recent statement (http://1.usa.gov/294CN9P).

First Page Preview View Large
First page PDF preview
First page PDF preview
×